Literature DB >> 19398608

Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling.

Aya Shinozaki1, Tetsuo Ushiku, Teppei Morikawa, Rumi Hino, Takashi Sakatani, Hiroshi Uozaki, Masashi Fukayama.   

Abstract

Epstein-Barr virus (EBV)-associated gastric carcinoma (GC) is a distinct subtype with characteristic clinicopathological features. To better characterize its cellular characteristics, 43 cases of EBV-associated GC, 68 cases of EBV-negative GC, and non-neoplastic gastric mucosa in adults and fetuses were examined immunohistochemically. We quantified the expression of the major tight-junction protein claudin (CLDN) -1, -3, -4, -7, and -18 together with gastric mucins (MUC5AC and MUC6), intestinal mucin (MUC2), and CD10. EBV-associated GC showed a high frequency of CLDN18 expression (84%) and a low frequency of CLDN3 expression (5%). This expression profile corresponded to that of normal gastric epithelium in adults and fetuses. Almost half of the EBV-associated GC cases demonstrated gastric mucin expression, whereas the other half lacked mucin or CD10 expression. In contrast, as demonstrated by the expression profiles of CLDN3 and CLDN18, EBV-negative GC comprised a heterogeneous group of four different CLDN phenotypes: gastric, intestinal, mixed, and an undifferentiated type with variable expression patterns of mucins. These results indicate that EBV-associated GC is considerably homogenous with regard to cellular differentiation and that it preserves well the nature of the cells of origin. EBV-associated GC may undergo distinct carcinogenic processes, which differ from those of EBV-negative GC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398608      PMCID: PMC2713077          DOI: 10.1369/jhc.2009.953810

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  25 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 2.  Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma.

Authors:  Masashi Fukayama; Rumi Hino; Hiroshi Uozaki
Journal:  Cancer Sci       Date:  2008-07-04       Impact factor: 6.716

3.  Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis.

Authors:  Adam H Johnson; Henry F Frierson; Alexander Zaika; Steven M Powell; James Roche; Sheila Crowe; Christopher A Moskaluk; Wa'el El-Rifai
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

4.  Global and non-random CpG-island methylation in gastric carcinoma associated with Epstein-Barr virus.

Authors:  Ja-Mun Chong; Kazuya Sakuma; Makoto Sudo; Tetsuo Ushiku; Hiroshi Uozaki; Junji Shibahara; Hideo Nagai; Nobuaki Funata; Hirokazu Taniguchi; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Cancer Sci       Date:  2003-01       Impact factor: 6.716

5.  CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.

Authors:  Moon-Sung Chang; Hiroshi Uozaki; Ja-Mun Chong; Tetsuo Ushiku; Kazuya Sakuma; Shunpei Ishikawa; Rumi Hino; Rita Rani Barua; Yoshiaki Iwasaki; Kuniyoshi Arai; Hideki Fujii; Hideo Nagai; Masashi Fukayama
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

6.  Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype.

Authors:  Y Soini; S Tommola; H Helin; P Martikainen
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

Review 7.  Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance?

Authors:  Hugo Sousa; Ana-L Pinto-Correia; Rui Medeiros; Mario Dinis-Ribeiro
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

8.  Gastric and intestinal claudin expression at the invasive front of gastric carcinoma.

Authors:  Yoshiko Matsuda; Shuho Semba; Junya Ueda; Takeichi Fuku; Tadateru Hasuo; Hideki Chiba; Norimasa Sawada; Yoshikazu Kuroda; Hiroshi Yokozaki
Journal:  Cancer Sci       Date:  2007-04-24       Impact factor: 6.716

9.  Clinicopathological and prognostic significance of mucin phenotype in gastric cancer.

Authors:  Kohei Wakatsuki; Yukishige Yamada; Michihiro Narikiyo; Masato Ueno; Tomoyoshi Takayama; Hidetoshi Tamaki; Katsuhiko Miki; Sohei Matsumoto; Koji Enomoto; Tomoyo Yokotani; Yoshiyuki Nakajima
Journal:  J Surg Oncol       Date:  2008-08-01       Impact factor: 3.454

Review 10.  Pores in the wall: claudins constitute tight junction strands containing aqueous pores.

Authors:  S Tsukita; M Furuse
Journal:  J Cell Biol       Date:  2000-04-03       Impact factor: 10.539

View more
  17 in total

1.  Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.

Authors:  Shiho Asaka; Tomoyuki Nakajima; Kaori Kugo; Risako Kashiwagi; Nozomi Yazaki; Tsutomu Miyamoto; Takeshi Uehara; Hiroyoshi Ota
Journal:  Virchows Arch       Date:  2020-01-13       Impact factor: 4.064

2.  Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma.

Authors:  Aya Shinozaki; Junji Shibahara; Naohiro Noda; Mariko Tanaka; Taku Aoki; Norihiro Kokudo; Masashi Fukayama
Journal:  Virchows Arch       Date:  2011-05-24       Impact factor: 4.064

3.  Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status.

Authors:  Shiho Asaka; Hiroyoshi Ota; Tomoyuki Nakajima; Koichi Ida; Ryoichi Asaka; Chinatsu Kobayashi; Masayuki Ito; Tsutomu Miyamoto; Takeshi Uehara
Journal:  Virchows Arch       Date:  2021-09-28       Impact factor: 4.064

4.  Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.

Authors:  Keren Jia; Yang Chen; Yu Sun; Yajie Hu; Lei Jiao; Jie Ma; Jiajia Yuan; Changsong Qi; Yanyan Li; Jifang Gong; Jing Gao; Xiaotian Zhang; Jian Li; Cheng Zhang; Lin Shen
Journal:  BMC Med       Date:  2022-07-11       Impact factor: 11.150

5.  Gastric carbonic anhydrase IX deficiency: At base, it is all about acid.

Authors:  Y Akiba; J D Kaunitz
Journal:  Acta Physiol (Oxf)       Date:  2018-02-21       Impact factor: 6.311

Review 6.  Host genetics of Epstein-Barr virus infection, latency and disease.

Authors:  Charlotte J Houldcroft; Paul Kellam
Journal:  Rev Med Virol       Date:  2014-11-27       Impact factor: 6.989

7.  Malignant transformation of hyperplastic gastric polyps: An immunohistochemical and pathological study of the changes of neoplastic phenotype.

Authors:  Johji Imura; Shinichi Hayashi; Kazuhito Ichikawa; Shigeharu Miwa; Takahiko Nakajima; Kazuhiro Nomoto; Koichi Tsuneyama; Tatsuya Nogami; Hitoaki Saitoh; Takahiro Fujimori
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

8.  Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.

Authors:  Keisuke Matsusaka; Tetsuo Ushiku; Masayuki Urabe; Masaki Fukuyo; Hiroyuki Abe; Shumpei Ishikawa; Yasuyuki Seto; Hiroyuki Aburatani; Takao Hamakubo; Atsushi Kaneda; Masashi Fukayama
Journal:  Oncotarget       Date:  2016-09-27

9.  Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.

Authors:  Weihua Tang; Douglas R Morgan; Michael O Meyers; Ricardo L Dominguez; Enrique Martinez; Kennichi Kakudo; Pei Fen Kuan; Natalie Banet; Hind Muallem; Kimberly Woodward; Olga Speck; Margaret L Gulley
Journal:  Infect Agent Cancer       Date:  2012-08-28       Impact factor: 2.965

10.  Profiling of immune related genes silenced in EBV-positive gastric carcinoma identified novel restriction factors of human gammaherpesviruses.

Authors:  Guillaume N Fiches; Dawei Zhou; Weili Kong; Ayan Biswas; Elshafa H Ahmed; Robert A Baiocchi; Jian Zhu; Netty Santoso
Journal:  PLoS Pathog       Date:  2020-08-25       Impact factor: 7.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.